OrbiMed Discloses 11% Stake in Electra Therapeutics After IPO Conversion
ETRA is trading near its 52-week low of $11.27 (1.4% above the low) on light trading volume (0.3× avg).
Summary
OrbiMed Advisors disclosed an 11.0% stake in Electra Therapeutics following the company's IPO, built from preferred stock conversions and direct IPO purchases, with board representation through Carl L. Gordon.
Key Events · Ownership and Investor Activity · ETRA
-
OrbiMed Holds 11% Stake
OrbiMed Advisors and affiliated entities beneficially own 6,885,170 shares of Electra Therapeutics, representing 11.0% of the 62,766,955 outstanding shares.
-
Preferred Stock Conversion
The stake was built through Series A, B, and C preferred stock investments from February 2022 through June 2026, all of which converted to common shares upon the IPO. A 1-for-1.5002 reverse split was applied to Series B and C preferred stock in September 2026.
-
IPO Purchases
OrbiMed entities purchased 1,333,333 shares in the IPO at $15.00 per share: 333,333 shares by OPI VII and 1,000,000 shares by Genesis.
-
Board Representation
Carl L. Gordon, a member of OrbiMed Advisors, serves on Electra's Board of Directors and is obligated to transfer any equity compensation received to OrbiMed Advisors.
Analysis · ETRA · Life Sciences
OrbiMed Advisors, a leading healthcare investment firm, now beneficially owns 6,885,170 shares of Electra Therapeutics, representing 11.0% of the company's outstanding stock. The stake was built through preferred stock investments dating back to February 2022, which converted to common shares upon the company's September 21 IPO. OrbiMed also purchased an additional 1,333,333 shares in the IPO at $15.00 per share. Carl L. Gordon, a member of OrbiMed Advisors, sits on Electra's board of directors, giving the firm both significant ownership and governance influence. The stock currently trades at $11.43, below the $15.00 IPO price, and near its 52-week low of $11.27.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 29.9% of the 1661 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ETRA was trading at $11.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $725M. The 52-week trading range was $11.27 to $15.50. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.